MS and Demyelinating Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Neurologist Michael Levy, MD, PhD, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.

Phase 3 data presented at AAN 2026 show that IVIG improves response rates in patients with autoimmune encephalitis refractory to steroids, supporting its role as a second-line immunotherapy option.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

New findings presented at AAN 2025 showed that treatment with satralizumab was associated with a reduction in annualized relapse rate compared with placebo over 48 weeks in patients with MOGAD.

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

Experts Laura Saucier, MD, MSc, and Jonathan Santoro, MD, examined pediatric MOGAD phenotypes, highlighting how variability in clinical presentation may influence treatment responses and inform individualized care strategies.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

A recent study revealed that a substantial proportion of patients with NMOSD required escalation from first-line immunosuppressants to rituximab, with baseline severe disability emerging as a key associated factor.

A recent study reported that relapse prevention was the most influential factor in treatment selection, with respondents favoring profiles similar to ravulizumab over other approved options for NMOSD.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Here's some of what is coming soon to NeurologyLive® this week.

Real-world MOGAD data show tocilizumab drives relapse-free control, improves disability and vision, but requires infection monitoring.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

A multicenter study showed that kappa free light chain index offers strong diagnostic accuracy for distinguishing MS from MOGAD and NMOSD, with added value when combined with oligoclonal band testing in complex cases.

A small case series published in JAMA Neurology found interstitial lung disease in 9% of long-term ocrelizumab-treated patients, with cases emerging after a mean of 10.5 years of therapy.

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

A new post hoc analysis of the CHAMPION-NMOSD trial reported similar safety and relapse prevention outcomes with ravulizumab-cwvz in patients with and without prior rituximab exposure.

Findings from a recently published study suggest peripapillary retinal nerve fiber layer thickness measured by OCT could support clinicians with early distinction between MOGAD-optic neuritis and NMOSD-optic neuritis.

Here's some of what is coming soon to NeurologyLive® this week.